Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov 12;8(21):5458-5466.
doi: 10.1182/bloodadvances.2024013743.

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Narendranath Epperla  1   2 , Ying Huang  1 , Amanda F Cashen  3 , John L Vaughn  1   4 , Walter Hanel  1 , Talha Badar  5   6 , Stefan K Barta  7   8 , Paolo F Caimi  9   10 , Tarsheen K Sethi  4   11 , Nishitha Reddy  11 , Reem Karmali  12 , Celeste Bello  13 , Julio C Chavez  13 , Shalin K Kothari  4   14 , Francisco J Hernandez-Ilizaliturri  14 , Jakub Svoboda  8 , Frederick Lansigan  15 , Martha J Glenn  2 , Jonathon B Cohen  16 , Caryn Sorge  17 , Beth Christian  1 , Alex F Herrera  18 , Mehdi Hamadani  5 , Luciano J Costa  19 , Ana C Xavier  20
Affiliations
Multicenter Study

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Narendranath Epperla et al. Blood Adv. .

Abstract

There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Classical Hodgkin Lymphoma patients wIth Primary treatment failure and analySis of outcomEs) is a multicenter retrospective cohort of patients with PTF-cHL (aged ≥15 years) diagnosed on or after 1 January 2005, at 15 US medical centers. PTF was defined as 1 of the following patterns of failure: (1) progressive disease by imaging during or within 6 weeks of completion of frontline chemotherapy (primary progression [PP]); (2) partial response (PR) or stable disease (SD) by imaging after completion of frontline treatment (PR/SD); (3) progression of disease by imaging (and confirmed by biopsy) within 12 months of frontline therapy completion after prior documentation of complete response (CR; early relapse [ER]). A total of 478 patients were included in the analysis. Among these, 217 (45%) were PP, 86 (18%) were PR/SD, and 175 (37%) were ER. The 6-month and 1-year cumulative incidence of nonrelapse mortality after auto-HCT were 0.9% and 1.1%, respectively. The median progression-free survival (PFS) and overall survival (OS) after auto-HCT were 4.33 and 10.09 years, respectively. Although those not in CR at the time of auto-HCT were associated with inferior PFS and OS, advanced age and diagnosis before 2011 were associated with inferior OS. This study showcases the safety and long-term efficacy of auto-HCT, even in patients with high-risk disease who are traditionally considered chemotherapy refractory, and will serve as a benchmark for the ongoing transplant vs no transplant trials.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.E. reports research funding from BeiGene and Eli Lilly; speakers' bureau fees from BeiGene and Genentech; advisory board fees from ADC Therapeutics, Ipsen, and Lilly; and consultancy fees from Novartis. M.H. reports research support/funding from Takeda Pharmaceutical Company, ADC Therapeutics, Spectrum Pharmaceuticals, and Astellas Pharma; consultancy fees from ADC Therapeutics, Omeros, CRISPR Therapeutics, Bristol Myers Squibb (BMS), Kite, AbbVie, Caribou, Genmab, and CRISPR; speakers' bureau fees from ADC Therapeutics, AstraZeneca, BeiGene, and Kite; and data monitoring committee fees from Genentech, Myeloid Therapeutics, and CRISPR Therapeutics. F.J.H.-I. reports advisory board fees from Incyte, Epizyme/Ipsen, BMS, BioGene, Amgen, AbbVie, Kite, Gilead, Collecter, Dava Oncology, Novartis, and ADC Therapeutics. S.K.B. reports advisory board/consulting fees from Affimed, Acrotech, Daiichi Sankyo, Kyowa Kirin, and Seagen, and data and safety monitoring committee fees from Janssen. R.K. reports advisory board fees from BMS, Gilead Sciences/Kite Pharma, Janssen, Karyopharm, Pharmacyclics, MorphoSys, Epizyme, Genentech/Roche, EUSA Pharma, and Calithera; grants/research support from BMS, Takeda, BeiGene, Gilead Sciences/Kite, and Calithera; and speakers' bureau fees from AstraZeneca, BeiGene, and MorphoSys. J.B.C. reports consultant/adviser fees from AstraZeneca, AbbVie, BeiGene, Janssen, Loxo/Lilly, Kite/Gilead, and ADC Therapeutics, and research funding from Leukemia and Lymphoma Society, Genentech, AstraZeneca, Novartis, Loxo/Lilly, and BMS/Celgene. J.S. reports research funding from Adaptive Biotechnologies, AstraZeneca, BMS, Incyte, Kite, Merck, Pharmacyclics, Seagen, and TG Therapeutics, and consulting fees from Adaptive Biotechnologies, AstraZeneca, Atara Biotherapeutics, BMS, CRISPR Therapeutics, Pharmacyclics, and Seagen. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
PFS for patients with PTF undergoing auto-HCT. (A) All patients. (B) Based on the disease status at auto-HCT. (C) Based on the category of PTF. NR, not reached.
Figure 1.
Figure 1.
PFS for patients with PTF undergoing auto-HCT. (A) All patients. (B) Based on the disease status at auto-HCT. (C) Based on the category of PTF. NR, not reached.
Figure 2.
Figure 2.
OS for patients with PTF undergoing auto-HCT. (A) All patients. (B) Based on the category of PTF. NR, not reached.
See this image and copyright information in PMC

References

    1. Blum KA. Controversies in the management of early-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2021;2021(1):234–239. - PMC - PubMed
    1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607. - PubMed
    1. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429. - PMC - PubMed
    1. Kreissl S, Goergen H, Buehnen I, et al. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e398–e409. - PubMed
    1. Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med. 2022;387(4):310–320. - PubMed

Publication types